Global Vesicoureteral Reflux Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Primary Vesicoureteral Reflux, Secondary Vesicoureteral Reflux.

By Diagnosis;

Voiding Cystourethrogram (VCUG), Ultrasound, Scintigraphy, Urinalysis, Others.

By Drug Treatment;

Quinolones, Aminoglycosides, Β-Lactam, Azoles, Others.

By Surgery ;

Open Surgery, Robotic-Assisted Laparoscopic Surgery, Endoscopic Surgery, and Others.

By End Users ;

Hospitals And Clinics, Academics And Research, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn209311071 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Vesicoureteral Reflux Market (USD Million), 2021 - 2031

In the year 2024, the Global Vesicoureteral Reflux Market was valued at USD 2,194.40 million. The size of this market is expected to increase to USD 3,222.55 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.6%.

Vesicoureteral reflux (VUR) presents a significant medical concern, particularly in the pediatric population. This condition, characterized by the abnormal flow of urine from the bladder back up into the ureters and sometimes into the kidneys, can lead to urinary tract infections (UTIs) and kidney damage if left untreated. The management of VUR often requires a multifaceted approach involving pharmacotherapy, surgical interventions, and close monitoring to mitigate associated risks and improve patient outcomes.

In recent years, advancements in diagnostic techniques, such as voiding cystourethrography and radionuclide cystography, have enhanced the accuracy of VUR diagnosis. Additionally, there has been a growing emphasis on non-invasive imaging modalities like ultrasound and magnetic resonance imaging (MRI), offering clinicians valuable tools for early detection and assessment of VUR severity.

The treatment landscape for VUR continues to evolve, with a range of options tailored to individual patient needs. Antibiotic prophylaxis remains a cornerstone in managing VUR-related UTIs, while surgical interventions like ureteral reimplantation or endoscopic injection of bulking agents are considered in cases of persistent or severe reflux. Moreover, ongoing research into novel pharmacological agents and minimally invasive procedures holds promise for further improving outcomes and reducing the burden of VUR on patients and healthcare systems globally.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Surgery
    2. Market Snapshot, By End Users
    3. Market Snapshot, By Region
  4. Global Vesicoureteral Reflux Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advancements in Diagnostic Technologies
        2. Increasing Awareness about Vesicoureteral Reflux (VUR)
        3. Growing Demand for Minimally Invasive Treatments
      2. Restraints
        1. Limited Access to Healthcare Facilities in Developing Regions
        2. High Cost of Treatment Options
        3. Stringent Regulatory Approval Processes
      3. Opportunities
        1. Rising Investments in Healthcare Infrastructure
        2. Focus on Pediatric Urology Research
        3. Emerging Markets Expansion

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Compititive Rivalry
  5. Market Segmentation
    1. Global Vesicoureteral Reflux Market, By Type , 2021 - 2031 (USD Million)
      1. Primary Vesicoureteral Reflux
      2. Secondary Vesicoureteral Reflux
    2. Global Vesicoureteral Reflux Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Voiding Cystourethrogram (VCUG)
      2. Ultrasound
      3. Scintigraphy
      4. Urinalysis
      5. Others
    3. Global Vesicoureteral Reflux Market, By Drug Treatment, 2021 - 2031 (USD Million)
      1. Quinolones
      2. Aminoglycosides
      3. Β-Lactam
      4. Azoles
      5. Others
    4. Global Vesicoureteral Reflux Market, By Surgery , 2021 - 2031 (USD Million)
      1. Open Surgery
      2. Robotic-Assisted Laparoscopic Surgery
      3. Endoscopic Surgery
      4. Others
    5. Global Vesicoureteral Reflux Market, By End Users , 2021 - 2031 (USD Million)
      1. Hospitals And Clinics
      2. Academics And Research
      3. Others
    6. Global Vesicoureteral Reflux Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Salix Pharmaceuticals
      2. Q-Med Scandinavia Inc
      3. Cook Medical
      4. Salix Pharmaceuticals Ltd
      5. Bayer AG
      6. Novartis AG
  7. Analyst Views
  8. Future Outlook of the Market